A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this 26 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
Eligibility Criteria
Inclusion Criteria: * Written informed consent. * ≥ 18 years old (male/female)). * CKD with eGFR \< 60 mL/min/1.73m²; not expected to need dialysis/ transplant during study. * 2 SBC values 12-21 mmol/L within 6 months pre-screening * During screening: 2 central SBC values 12-21 mmol/L * Willing to maintain stable diet . * Expect to keep oral alkali therapy dose stable. * Women of childbearing potential: negative pregnancy test and agree to abstinence or contraception. Exclusion Criteria: * Any participant deemed by the Investigator to be an inappropriate candidate for physical performance testing (e.g., severe musculoskeletal pain, non-ambulatory status) or with a screening STS5 time \< 10 seconds (i.e., very mobile). * Any participant deemed by the Investigator to be an inappropriate candidate for CPET (e.g., advanced chronic obstructive pulmonary disease \[COPD\], major cardiovascular \[CV\] event in last 6 months, systolic blood pressure \[SBP\] \> 200 mmHg or diastolic blood pressu